TR200103059T2 - Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı - Google Patents

Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı

Info

Publication number
TR200103059T2
TR200103059T2 TR2001/03059T TR200103059T TR200103059T2 TR 200103059 T2 TR200103059 T2 TR 200103059T2 TR 2001/03059 T TR2001/03059 T TR 2001/03059T TR 200103059 T TR200103059 T TR 200103059T TR 200103059 T2 TR200103059 T2 TR 200103059T2
Authority
TR
Turkey
Prior art keywords
disorders
norcisapride
bulimia
optically pure
treat apnea
Prior art date
Application number
TR2001/03059T
Other languages
English (en)
Inventor
D. Rubin Paul
J. Barberich Timothy
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of TR200103059T2 publication Critical patent/TR200103059T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

Apne, apne bozukluklari, bulimi nervosa, tahrisat yaratabilen bagirsak sendromu, idrarini tutamama, bradikardi, bradiaritimi, sinkop, baska bozukluklar ya da bunlarin semptomlarinin engellenmesi ya da kontrol altina alinmasi için, esas olarak (-) stereoizmerini barindirmayan (+) norsisaprid ya da farmasötik açidan kabul edilebilir bir tuzunun kullanimi.
TR2001/03059T 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı TR200103059T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US12227599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
TR200103059T2 true TR200103059T2 (tr) 2002-06-21

Family

ID=26780365

Family Applications (7)

Application Number Title Priority Date Filing Date
TR2001/03057T TR200103057T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03059T TR200103059T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03055T TR200103055T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03054T TR200103054T2 (tr) 1998-06-15 1999-06-10 Apne,bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03058T TR200103058T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
TR2000/03708T TR200003708T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
TR2001/03056T TR200103056T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/03057T TR200103057T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı

Family Applications After (5)

Application Number Title Priority Date Filing Date
TR2001/03055T TR200103055T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03054T TR200103054T2 (tr) 1998-06-15 1999-06-10 Apne,bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
TR2001/03058T TR200103058T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
TR2000/03708T TR200003708T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
TR2001/03056T TR200103056T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.

Country Status (26)

Country Link
US (4) US6048879A (tr)
EP (1) EP1089733B1 (tr)
JP (1) JP2002518352A (tr)
KR (3) KR20060017570A (tr)
CN (1) CN1312717A (tr)
AR (1) AR019671A1 (tr)
AT (1) ATE291427T1 (tr)
AU (1) AU4433399A (tr)
BG (1) BG105096A (tr)
BR (1) BR9911299A (tr)
CA (1) CA2333666A1 (tr)
CZ (1) CZ20004737A3 (tr)
DE (1) DE69924375T2 (tr)
ES (1) ES2237110T3 (tr)
HK (1) HK1040058A1 (tr)
HU (1) HUP0102203A3 (tr)
IL (1) IL140118A0 (tr)
IS (1) IS5756A (tr)
NO (1) NO20006357L (tr)
NZ (3) NZ508824A (tr)
PL (1) PL345275A1 (tr)
PT (1) PT1089733E (tr)
SI (1) SI1089733T1 (tr)
SK (1) SK19052000A3 (tr)
TR (7) TR200103057T2 (tr)
WO (1) WO1999065571A2 (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
TR200103757T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
AU779696B2 (en) * 1999-03-01 2005-02-10 Sepracor, Inc. Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
EP1435238A1 (en) * 1999-03-01 2004-07-07 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US7803195B2 (en) * 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
EP1833467B1 (en) 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
EP1984066B1 (en) 2006-02-16 2020-05-06 Imthera Medical, Inc. An rfid based system for therapeutic treatment of a patient
BRPI0817852A2 (pt) 2007-10-09 2015-04-07 Imthera Medical Inc Sistema e método de estimulação neural
US8428725B2 (en) 2008-10-09 2013-04-23 Imthera Medical, Inc. Method of stimulating a Hypoglossal nerve for controlling the position of a patient's tongue
WO2011059531A1 (en) 2009-11-10 2011-05-19 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1993012785A1 (en) * 1991-12-21 1993-07-08 Smithkline Beecham Plc Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
DE69818678T2 (de) * 1997-07-11 2004-07-15 Janssen Pharmaceutica N.V. (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten

Also Published As

Publication number Publication date
TR200103056T2 (tr) 2002-06-21
NO20006357L (no) 2001-02-13
US20020147220A1 (en) 2002-10-10
TR200003708T2 (tr) 2001-06-21
NZ508824A (en) 2003-10-31
SK19052000A3 (sk) 2001-06-11
US20050154018A1 (en) 2005-07-14
DE69924375T2 (de) 2005-08-11
HK1040058A1 (zh) 2002-05-24
TR200103057T2 (tr) 2002-06-21
PT1089733E (pt) 2005-08-31
WO1999065571A3 (en) 2000-04-20
CA2333666A1 (en) 1999-12-23
DE69924375D1 (de) 2005-04-28
PL345275A1 (en) 2001-12-03
CN1312717A (zh) 2001-09-12
US6835740B2 (en) 2004-12-28
ES2237110T3 (es) 2005-07-16
WO1999065571A2 (en) 1999-12-23
HUP0102203A2 (hu) 2001-11-28
AU4433399A (en) 2000-01-05
EP1089733A2 (en) 2001-04-11
KR20060067986A (ko) 2006-06-20
AR019671A1 (es) 2002-03-13
NZ526943A (en) 2004-11-26
JP2002518352A (ja) 2002-06-25
BG105096A (en) 2002-02-28
TR200103054T2 (tr) 2002-06-21
CZ20004737A3 (cs) 2001-10-17
TR200103058T2 (tr) 2002-06-21
ATE291427T1 (de) 2005-04-15
EP1089733B1 (en) 2005-03-23
HUP0102203A3 (en) 2001-12-28
US6048879A (en) 2000-04-11
TR200103055T2 (tr) 2002-06-21
KR20060017570A (ko) 2006-02-23
NZ535135A (en) 2006-04-28
NO20006357D0 (no) 2000-12-13
IS5756A (is) 2000-12-08
IL140118A0 (en) 2002-02-10
US6369079B1 (en) 2002-04-09
SI1089733T1 (en) 2005-06-30
BR9911299A (pt) 2001-03-13
KR20010052739A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
TR200103054T2 (tr) Apne,bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
NO20005448L (no) Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert på patologisk celleproliferering
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
AU3741801A (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
EA199901086A1 (ru) ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ p56
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
TR200003707T2 (tr) Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
TR199902719T2 (tr) Bilesikler.
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
PT1003554E (pt) Inibidor da bomba de protoes em combinacao terapeutica com substancias antibacterianas
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
ATE395060T1 (de) Verwendung von tenatoprazol zur behandlung von gastroösophogalem reflux
TR200000244T2 (tr) MCP-1 proteini üretimini azaltmada etkin bir farmasötik bileşim.